BioCentury | Oct 30, 2020
Deals

Via takeout of Atlas-grown optogenetic company for $150M up front, Novartis adds to gene therapy arsenal

Novartis’ acquisition of Atlas-incubated start-up Vedere Bio will bolster an ophthalmic gene therapy portfolio spearheaded by Luxturna, and will give the Swiss pharma technology to deliver gene therapies to the retina intravitreally.  Novartis AG (NYSE:NVS; SIX:NOVN)...
BioCentury | Oct 27, 2020
Product Development

Oct. 26 Quick Takes: COVID trips up Spectrum’s Rolontis at FDA; plus Jazz-SpringWorks, Novartis’ iptacopan, Kantaro, Eternygen

Delay for Spectrum due to COVID-19 travel restrictionsSpectrum Pharmaceuticals Inc. (NASDAQ:SPPI) said FDA is deferring action on the company’s BLA for its Rolontis eflapegrastim because the agency was unable to inspect Hanmi Bioplant, the drug substance...
BioCentury | Oct 24, 2020
Finance

Oct. 23 Quick Takes: RA Capital’s $461M new fund; plus venture rounds for Sirnaomics, 3D Medicines, Zhaoke, Orbus, Araris

New $461M venture fund for RA RA Capital raised $461 million for its Nexus Fund II, its second venture fund that like 2019’s $300 million Nexus I Fund will invest in private companies backed by the...
BioCentury | Oct 24, 2020
Product Development

Oct. 23 Quick Takes: Ultragenyx, Solid in DMD gene therapy deal; plus IAVI-Merck KGaA-Serum Institute, BiondVax, Retrophin-Orphan Technologies, and more

Ultragenyx, Solid Bio in deal for DMD gene therapyUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) is collaborating with Solid Biosciences Inc. (NASDAQ:SLDB) to develop a gene therapy for Duchenne muscular...
BioCentury | Oct 24, 2020
Translation in Brief

UNC Chapel Hill Angelman gene therapy rescues motor function; plus data backing planned Pacylex, Kronos clinical trials and more

AAV gene editing therapy for Angelman syndromeUniversity of North Carolina at Chapel Hill scientists have created a CRISPR gene therapy for Angelman syndrome that ameliorated motor function deficits in a mouse model of the maternally...
BioCentury | Oct 24, 2020
Emerging Company Profile

SparingVision’s line of sight to a mutation-agnostic gene therapy for ophthalmic disease

SparingVision thinks its neuroprotective AAV therapy could benefit all retinitis pigmentosa patients, including those missed by mutation-targeted gene replacement therapies like Luxturna. The Paris-based...
BioCentury | Oct 23, 2020
Emerging Company Profile

Be Bio: bringing the B to cell therapy

Be Biopharma launched Thursday with a $52 million series A round led by Atlas Venture and RA Capital and a platform to engineer B cells that could overcome the durability, safety and re-dosing challenges of existing cell...
BioCentury | Oct 23, 2020
Finance

SPAC to the future: an old-time IPO alternative may be back to stay

Investors and bankers believe specialist-backed SPACs could become a cyclical part of biotech's fund-raising equation with some clear advantages over traditional IPOs for the right type of company....
BioCentury | Oct 22, 2020
Politics, Policy & Law

Protecting biomedical innovation as a national security asset

In recent years, it has become fashionable to focus on the high price of new treatments for certain cancers and rare diseases. Many observers ask why it is that U.S. citizens should subsidize the rest...
BioCentury | Oct 21, 2020
Deals

With roots in Medivation, Nuvation finds quick route to listing via year’s largest SPAC deal

The team that backed Medivation is returning to the U.S. public markets as Nuvation with a fresh injection of $644 million through a reverse merger with EcoR1’s SPAC Panacea and a PIPE backed by 16...
Items per page:
1 - 10 of 4961
BioCentury | Oct 30, 2020
Deals

Via takeout of Atlas-grown optogenetic company for $150M up front, Novartis adds to gene therapy arsenal

Novartis’ acquisition of Atlas-incubated start-up Vedere Bio will bolster an ophthalmic gene therapy portfolio spearheaded by Luxturna, and will give the Swiss pharma technology to deliver gene therapies to the retina intravitreally.  Novartis AG (NYSE:NVS; SIX:NOVN)...
BioCentury | Oct 27, 2020
Product Development

Oct. 26 Quick Takes: COVID trips up Spectrum’s Rolontis at FDA; plus Jazz-SpringWorks, Novartis’ iptacopan, Kantaro, Eternygen

Delay for Spectrum due to COVID-19 travel restrictionsSpectrum Pharmaceuticals Inc. (NASDAQ:SPPI) said FDA is deferring action on the company’s BLA for its Rolontis eflapegrastim because the agency was unable to inspect Hanmi Bioplant, the drug substance...
BioCentury | Oct 24, 2020
Finance

Oct. 23 Quick Takes: RA Capital’s $461M new fund; plus venture rounds for Sirnaomics, 3D Medicines, Zhaoke, Orbus, Araris

New $461M venture fund for RA RA Capital raised $461 million for its Nexus Fund II, its second venture fund that like 2019’s $300 million Nexus I Fund will invest in private companies backed by the...
BioCentury | Oct 24, 2020
Product Development

Oct. 23 Quick Takes: Ultragenyx, Solid in DMD gene therapy deal; plus IAVI-Merck KGaA-Serum Institute, BiondVax, Retrophin-Orphan Technologies, and more

Ultragenyx, Solid Bio in deal for DMD gene therapyUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) is collaborating with Solid Biosciences Inc. (NASDAQ:SLDB) to develop a gene therapy for Duchenne muscular...
BioCentury | Oct 24, 2020
Translation in Brief

UNC Chapel Hill Angelman gene therapy rescues motor function; plus data backing planned Pacylex, Kronos clinical trials and more

AAV gene editing therapy for Angelman syndromeUniversity of North Carolina at Chapel Hill scientists have created a CRISPR gene therapy for Angelman syndrome that ameliorated motor function deficits in a mouse model of the maternally...
BioCentury | Oct 24, 2020
Emerging Company Profile

SparingVision’s line of sight to a mutation-agnostic gene therapy for ophthalmic disease

SparingVision thinks its neuroprotective AAV therapy could benefit all retinitis pigmentosa patients, including those missed by mutation-targeted gene replacement therapies like Luxturna. The Paris-based...
BioCentury | Oct 23, 2020
Emerging Company Profile

Be Bio: bringing the B to cell therapy

Be Biopharma launched Thursday with a $52 million series A round led by Atlas Venture and RA Capital and a platform to engineer B cells that could overcome the durability, safety and re-dosing challenges of existing cell...
BioCentury | Oct 23, 2020
Finance

SPAC to the future: an old-time IPO alternative may be back to stay

Investors and bankers believe specialist-backed SPACs could become a cyclical part of biotech's fund-raising equation with some clear advantages over traditional IPOs for the right type of company....
BioCentury | Oct 22, 2020
Politics, Policy & Law

Protecting biomedical innovation as a national security asset

In recent years, it has become fashionable to focus on the high price of new treatments for certain cancers and rare diseases. Many observers ask why it is that U.S. citizens should subsidize the rest...
BioCentury | Oct 21, 2020
Deals

With roots in Medivation, Nuvation finds quick route to listing via year’s largest SPAC deal

The team that backed Medivation is returning to the U.S. public markets as Nuvation with a fresh injection of $644 million through a reverse merger with EcoR1’s SPAC Panacea and a PIPE backed by 16...
Items per page:
1 - 10 of 4961